Trials / Terminated
TerminatedNCT03319537
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pevonedistat | Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient. |
| DRUG | Pemetrexed and cisplatin | Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle. |
Timeline
- Start date
- 2017-10-05
- Primary completion
- 2023-06-05
- Completion
- 2023-06-05
- First posted
- 2017-10-24
- Last updated
- 2024-05-23
- Results posted
- 2024-05-23
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03319537. Inclusion in this directory is not an endorsement.